

Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. *Blood Adv.* 2023;7(6):900-908.

On page 900, the first Key Point, which reads “There was no evidence of fibrinolytic activation in patients with hypoproliferative anemia” should read “No evidence of fibrinolytic activation was observed in patients with hypoproliferative thrombocytopenia.”

<https://doi.org/10.1182/bloodadvances.2023010270>

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.